
Uppsala Reports editor
@UMCGlobalSafety
Medicine safety monitoring applies to all aspects of drug development, but how much is it impacted by patient diversity and study type in clinical trials?
Medicine safety monitoring is important in every stage of drug development, from pre-marketing clinical trials to post-marketing analyses. Yet, certain factors in their design can greatly impact its effectiveness, such as the diversity of the study population, or the complexity of its methodology.
All this and more is discussed in the latest Drug Safety Matters podcast episode, where Marianne Lunzer from AGES and Sanja Prpić from HALMED, review the pros and cons of various study types and the importance of testing medicines on diverse populations, as well as how pre and post-marketing studies are linked to give a more comprehensive picture of patient safety.
Subscribe by visiting the Drug Safety Matters website or listen to the podcast here:
The theme of this year’s ISoP mid-year symposium encouraged members to reflect on how PV scientists may work better with clinicians to ensure medicine safety for their patients.
Research / 28 June 2023
There is much to be gained from using VigiBase to further explore known adverse reactions to drugs, as some may be having more of an impact on patients than first thought.
Research / 18 September 2023
Herbal remedies have been used for thousands of years to treat what ails us. Yet why do we still know so little about their potential side effects compared to modern medicines?
Research / 29 August 2023